

## Introduction

FEDERG is the non-profit federation of European associations of patients affected by rare and/or genetic kidney diseases. To further its aims, FEDERG seeks funding and support from a variety of sources in addition to voluntary income from its supporters (donations and fundraising activities).

FEDERG works with, and accepts sponsorship, grants, fees for service and funding from pharmaceutical companies when this is in the interests of people affected by rare and/or genetic kidney disease.

In addition, FEDERG has a role to play in facilitating the relationship between academia and the pharmaceutical industry.

The purpose of this policy is to ensure that in seeking and securing such funding, FEDERG has a clearly understood, ethical way of working collaboratively with the pharmaceutical industry. This document should be read in conjunction with FEDERG Ethical Collaboration Policy.

## Guiding Principles

- Pharmaceutical companies must comply with the standards set out in the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Code of Practice 2019 – in particular Article 11 ‘Interactions with Patient Organisations’ – and equivalent European Codes where relevant.
- Any collaborations and projects must clearly support FEDERG’s charitable purpose, aims, and objectives.
- FEDERG will be transparent in our partnerships with the pharmaceutical industry and seek support from more than one company whenever we can.
- FEDERG will never give one company a competitive advantage over another.
- Expectations and requirements of both/all parties to collaborations or funding agreements will be recorded in writing.
- Publications or products resulting from pharmaceutical industry sponsorship will carry FEDERG logo; copyright and any intellectual property generated will remain with FEDERG.
- The total proportion of FEDERG’s annual income received from any one pharmaceutical and biotechnology companies shall not exceed 30% of FEDERG’s total annual income. Should circumstances arise where this percentage is likely to be exceeded, approval of the board will be sought. This funding will be published within FEDERG annual report.

## Contact

Tess Harris, President

Email: [info@federg.org](mailto:info@federg.org) | Tel: +44 (0) 20 7387 0543